guidance

Hikma continues strong momentum across the Group and upgrades guidance for 2023

Hikma continues strong momentum across the Group and upgrades guidance for 2023

AETOSWire sarjatha 2 November، 2023

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update...

Hikma delivers strong H1 performance and raises Generics guidance Growth in all three businesses and across all geographies

Hikma delivers strong H1 performance and raises Generics guidance Growth in all three businesses and across all geographies

Hikma delivers strong H1 performance and raises Generics guidance Growth in all three businesses and across all geographies

AETOSWire sarjatha 3 August، 2023

Hikma Pharmaceuticals PLC and its subsidiaries (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, report its interim results...

Hikma reiterates full year segmental guidance, with strong momentum in Injectables and Branded

Hikma reiterates full year segmental guidance, with strong momentum in Injectables and Branded

AETOSWire sarjatha 3 November، 2022

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update...

Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition

Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition

Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition

AETOSWire sarjatha 29 April، 2022

London, England – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on...